Jean-Marc Bellemin
Directeur Financier/CFO chez IOVANCE BIOTHERAPEUTICS, INC.
Fortune : 675 967 $ au 30/04/2024
Postes actifs de Jean-Marc Bellemin
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Comptroller/Controller/Auditor | 11/03/2021 | - |
| Directeur Financier/CFO | 14/12/2020 | - | |
| Treasurer | 14/12/2020 | - |
Historique de carrière de Jean-Marc Bellemin
Anciens postes connus de Jean-Marc Bellemin
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GRITSTONE BIO, INC. | Directeur Financier/CFO | 01/01/2018 | 11/12/2020 |
Actelion Pharmaceuticals US, Inc.
 Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals US, Inc. is a private company that manufactures, distributes and markets drugs. The company is based in Titusville, NJ. The CEO of the company is Samuele Butera. | Corporate Officer/Principal | 01/01/2008 | 01/12/2017 |
Formation de Jean-Marc Bellemin
| Université Paris Dauphine-PSL | Undergraduate Degree |
| Université Paris II Panthéon Assas | Graduate Degree |
| ESSEC Business School | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 4 |
| France | 4 |
Opérationnelle
| Director of Finance/CFO | 2 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GRITSTONE BIO, INC. | Health Technology |
| IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Actelion Pharmaceuticals US, Inc.
Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals US, Inc. is a private company that manufactures, distributes and markets drugs. The company is based in Titusville, NJ. The CEO of the company is Samuele Butera. | Health Technology |
- Bourse
- Insiders
- Jean-Marc Bellemin
- Expérience
